Shohei Koide
Professor - Biologics Design New York University Grossman School of Medicine
Seminars
Thursday 18th September 2025
Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
2:00 pm
- Uncovering preclinical evidence to showcase the potential for NRAS and HRAS-targeting programs
- How to selectively target NRAS or HRAS and minimize off-target effects
- How to develop a successful patient stratification strategy for clinical trials related to NRASmutant and HRAS-mutant cancer
Thursday 18th September 2025
Leveraging Strategies for Selective Targeting of NRAS & Q61 Mutations for Cancer Treatment
1:30 pm
- Synthetic binding proteins are powerful tools for examining the feasibility of achieving unprecedented specificity and discovering new druggable sites
- We have developed monobodies, synthetic binding proteins, that show pan-NRAS and Q61Xselective specificity profiles, and defined their structural bases
- A new protein delivery technology enables efficient and selective inhibition of RAS signaling with monobodies, expanding their utility as tool biologics and potential therapeutics
